Connect with us

Hi, what are you looking for?

Health

Clinical trials of inhaled version of drug to treat COVID-19 to begin

Liptovsky Hradok, Slovakia - April 20, 2020: Remdesivir instructions label on small medical bottle,space for text right. GS-5734 is antiviral drug developed Gilead Sciences, possible coronavirus cure

The company behind the only drug approved by the U.S. Food and Drug Administration for treatment of COVID-19 announced Monday plans to begin clinical trials of an inhaled version of the drug, which, if proven beneficial, could make it easier to administer and treat people earlier. 

In an open letter posted to Gilead Sciences website Monday, the company’s chairman and CEO, Daniel O’Day, wrote that they hope to begin clinical trials in August. 

“After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of Remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August,” O’Day said. “If the trials are successful, this could represent important progress.” 

Remdesivir is currently given to patients intravenously through daily infusions in the hospital. Early results of a large clinical trial of the drug showed that those who received remdesivir, rather than a placebo, recovered 31 percent faster. 

“An inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside the hospital, at earlier stages of disease. That could have significant implications in helping to stem the tide of the pandemic,” O’Day wrote in his letter. 

Remdesivir doesn’t work as well on COVID-19 patients who are experiencing more severe symptoms, and for those who require ventilation, however. 

There is also currently a limited supply of the drug, Alabama physicians have said in recent press briefings. 

Advertisement. Scroll to continue reading.

“Although the total supply of remdesivir is limited, we are grateful that hospitalized COVID-19 patients with severe disease in Alabama can receive this potentially lifesaving medication,” Alabama State Health Officer Dr. Scott Harris said in a statement in May. “Because the quantity is limited, the physician members of the Governor’s Coronavirus (COVID-19) Task Force determined a formula to distribute the allotment equitably among the state’s hospitals.”

Dr. Robert Kadlec, the assistant secretary for preparedness and response at the U.S. Department of Health and Human Services, told CNN that the U.S. government’s supply of Remdesivir will run out at the end of June. 

“Right now, we’re waiting to hear from Gilead what is their expected delivery availability of the drug as we go from June to July,” Kadlec told CNN. “We’re kind of not in negotiations, but in discussions with Gilead as they project what the availability of their product will be.”

Eddie Burkhalter is a reporter at the Alabama Political Reporter. You can email him at [email protected] or reach him via Twitter.

More from the Alabama Political Reporter

Legislature

At a recent Board of Veterans Affairs meeting, members questioned Oliver's fitness to serve as House veterans affairs committee chair.

Health

The growth accounts for the steepest single increase in the COVID-19 positivity rate in some time.

Featured Opinion

When it comes to COVID and the COVID vaccine, conspiracy theories abound. Which is weird, since reality is sitting right there.

Economy

The NFIB Research Center’s latest COVID-19 survey assesses the impact the COVID-19 pandemic has had on small businesses.

Health

The state's COVID-19 positivity rate has risen at an alarming rate over the past two weeks.

Health

Although COVID-19 has been on a decline, UAB doctors say the return to normal activity has brought back a surge in flu and RSV.

Education

Alabama performed well compared to 28 other states, losing about one month in math and staying steady in reading.

Economy

Over the year, wage and salary employment increased by 53,800, representing the largest year-to-date growth of 2.6 percent.